Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A miniature DNA sequencing device that plugs into a laptop and was developed by Oxford Nanpore has been tested by an open, international consortium, including Oxford University researchers.

The MinION is the smallest high-throughput DNA-sequencing device currently available
The MinION is the smallest high-throughput DNA-sequencing device currently available

The results show that it provides good, repeatable results that can be just as useful as those provided by larger, more expensive devices.

The MinION is a handheld DNA-sequencing device developed by Oxford Nanopore, a spin-out company from the University of Oxford. The smallest high-throughput sequencing system currently available, the device can be plugged into any computer using a USB port, weighs just 90 grams and measures 10 centimetres in length. It works by detecting individual DNA bases that pass through a nanopore — a tiny hole in a membrane. When the DNA bases pass through or near the nanpore, they create a distinctive electrical current, allowing the device to read long DNA sequences in a way that is not possible on most other devices.

Read more

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.